Why the study?
Does trimetazidine improve right ventricular function and reduce apoptosis in preclinical models of right heart failure?
Population
In vitro cultivated right ventricular myocardial cells and left ventricular myocardial cells, and an in vivo…
Comparison
Trimetazidine vs Control (hypoxia/Su5416 without trimetazidine)
Design
Preclinical
Follow-up
24 hours (in vitro)
Authors
Loading...
Trimetazidine shows preclinical RV protection; leaves open human translation and miR-21 mechanism confirmation.
Does trimetazidine improve right ventricular function and reduce apoptosis in preclinical models of right heart failure?
Trimetazidine protects against right ventricular myocardial cell apoptosis and improves right ventricular function in preclinical models, potentially mediated by increased miR-21 expression.
Liu et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: